[Efficacy of methylprednisolone therapy for electrical status epilepticus during sleep in children]

Jing Chen1, Zhixian Yang1, Xiaoyan Liu1

  • 1The first author is now in Department of Neurology, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China.

Insights

Methylprednisolone effectively treated electrical status epilepticus during sleep (ESES) and seizures in children with three epilepsy syndromes. Treatment outcomes were not significantly correlated with age at seizure onset or ESES duration.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Pharmacology

Context:

  • Electrical status epilepticus during sleep (ESES) is a severe epilepsy syndrome in children.
  • Benign childhood epilepsy with centrotemporal spikes (BECT) variants, epilepsy with continuous spikes and waves during slow sleep (CSWS), and Landau-Kleffner syndrome (LKS) are associated with ESES.
  • Current treatment options for ESES require further evaluation.

Purpose:

  • To assess the therapeutic efficacy of methylprednisolone in pediatric patients diagnosed with ESES.
  • To evaluate the impact of methylprednisolone on ESES suppression and seizure control across different epilepsy syndromes.

Summary:

  • A study analyzed 82 pediatric epilepsy patients with ESES (BECT variants, CSWS, LKS) treated with methylprednisolone. The treatment involved intravenous methylprednisolone followed by oral prednisone.
  • Methylprednisolone demonstrated an 83% overall effective rate for ESES suppression and seizure improvement in the studied syndromes.
  • Seizures improved within the first month, though recurrence rates varied by syndrome after one year.

Impact:

  • Methylprednisolone is a viable therapeutic option for managing ESES and associated seizures in pediatric epilepsy.
  • The study highlights the effectiveness of corticosteroids in addressing ESES, offering a potential treatment pathway.
  • Findings suggest that treatment efficacy is independent of age at seizure onset or ESES duration, simplifying treatment considerations.
Abstract